Goldman Sachs Group Inc. Makes New $145,000 Investment in Maze Therapeutics, Inc. $MAZE

Goldman Sachs Group Inc. bought a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 13,129 shares of the company’s stock, valued at approximately $145,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Rhumbline Advisers acquired a new stake in Maze Therapeutics during the first quarter valued at approximately $80,000. Woodline Partners LP bought a new position in Maze Therapeutics during the 1st quarter valued at about $10,229,000. Octagon Capital Advisors LP acquired a new stake in shares of Maze Therapeutics during the 1st quarter worth approximately $5,153,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Maze Therapeutics during the first quarter valued at approximately $57,000. Finally, ARCH Venture Management LLC bought a new stake in shares of Maze Therapeutics in the first quarter worth $45,362,000.

Maze Therapeutics Stock Performance

MAZE opened at $25.20 on Tuesday. Maze Therapeutics, Inc. has a 52-week low of $6.71 and a 52-week high of $28.37. The business has a fifty day moving average of $17.23 and a 200 day moving average of $13.27.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.02.

Insider Buying and Selling at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the company’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on MAZE shares. Guggenheim increased their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Wedbush initiated coverage on Maze Therapeutics in a report on Tuesday, July 8th. They set an “outperform” rating and a $17.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Maze Therapeutics in a research note on Thursday, September 18th. JPMorgan Chase & Co. increased their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $33.83.

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.